Description

Niba Labs is a company specializing in cell and gene therapies that develops and provides advanced analytical services for the characterization of viral vectors (AAV, LVV, AV). Their work includes the development, optimization, and validation of dPCR assays for the precise quantification of viral genomes, as well as the conduct of comparability and bridging studies between analytical methods (dPCR, qPCR).

The company also performs analyses of impurities such as host cell DNA, plasmid DNA, and host cell proteins, as well as advanced NGS analyses for nucleic acid identification, genome integrity verification, and mutation detection. Additionally, they offer TEM analyses of viral particles and ELISA quantification of capsids.

Using their proprietary NibaPlex platform, they analyze the integrity of viral vectors and enable a precise assessment of the quality, safety, and efficacy of solutions in the field of cell and gene therapies. This is a multiplex digital PCR (dPCR) solution that enables precise quantification of complete and incomplete genomes and helps researchers assess the quality, safety, and efficacy of therapeutic viruses. The platform accelerates the development and validation of gene therapies by providing a more comprehensive insight into the structure of virus products.